Jeremy C Hobart

Summary

Affiliation: Peninsula Medical School
Country: UK

Publications

  1. doi request reprint Effect sizes can be misleading: is it time to change the way we measure change?
    Jeremy C Hobart
    Department of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, Room N16 ITTC Building, Tamar Science Park, Plymouth, Devon, UK
    J Neurol Neurosurg Psychiatry 81:1044-8. 2010
  2. ncbi request reprint Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations
    Jeremy C Hobart
    Neurological Outcome Measures Unit, Peninsula College of Medicine and Dentistry, Plymouth, Devon, UK
    Lancet Neurol 6:1094-105. 2007
  3. pmc The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?
    Stefan J Cano
    Neurological Outcome Measures Unit, Institute of Neurology, University College London, Queen Square, London, UK
    Health Qual Life Outcomes 6:58. 2008
  4. doi request reprint Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS
    Jeremy Hobart
    Plymouth University Peninsula Schools of Medicine and Dentistry, Devon, UK
    Neurology 80:1509-17. 2013
  5. doi request reprint Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory
    Jeremy Hobart
    Clinical Neurology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
    Alzheimers Dement 9:S10-20. 2013
  6. doi request reprint Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods
    Jeremy Hobart
    Clinical Neurology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
    Alzheimers Dement 9:S4-9. 2013
  7. pmc A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)
    Afsane Riazi
    Department of Psychology, Royal Holloway, University of London, Surrey, TW20 0EX, UK
    Health Qual Life Outcomes 9:80. 2011
  8. pmc The size of the treatment effect: do patients and proxies agree?
    Femke A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    BMC Neurol 9:12. 2009
  9. ncbi request reprint Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)
    J C Hobart
    Department of Clinical Neuroscience, Peninsula Medical School, Plymouth, Devon, UK
    Brain 129:224-34. 2006
  10. pmc How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales
    J C Hobart
    Murdoch University, Perth, Western Australia
    J Neurol Neurosurg Psychiatry 76:1539-43. 2005

Collaborators

Detail Information

Publications24

  1. doi request reprint Effect sizes can be misleading: is it time to change the way we measure change?
    Jeremy C Hobart
    Department of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, Room N16 ITTC Building, Tamar Science Park, Plymouth, Devon, UK
    J Neurol Neurosurg Psychiatry 81:1044-8. 2010
    ..To examine these concerns, in this study a sophisticated psychometric analysis was applied, Rasch measurement to BI and FIMm data...
  2. ncbi request reprint Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations
    Jeremy C Hobart
    Neurological Outcome Measures Unit, Peninsula College of Medicine and Dentistry, Plymouth, Devon, UK
    Lancet Neurol 6:1094-105. 2007
    ..We show that improvements in the scientific rigour of rating scales can improve the chances of reaching the correct conclusions about the effectiveness of treatments...
  3. pmc The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?
    Stefan J Cano
    Neurological Outcome Measures Unit, Institute of Neurology, University College London, Queen Square, London, UK
    Health Qual Life Outcomes 6:58. 2008
    ....
  4. doi request reprint Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS
    Jeremy Hobart
    Plymouth University Peninsula Schools of Medicine and Dentistry, Devon, UK
    Neurology 80:1509-17. 2013
    ..In this study, we used data from clinical trials of dalfampridine (fampridine outside the United States) to re-examine the clinical meaningfulness of Timed 25-Foot Walk (T25FW) changes...
  5. doi request reprint Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory
    Jeremy Hobart
    Clinical Neurology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
    Alzheimers Dement 9:S10-20. 2013
    ....
  6. doi request reprint Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods
    Jeremy Hobart
    Clinical Neurology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
    Alzheimers Dement 9:S4-9. 2013
    ..However, there are concerns about its use in early-stage disease. Herein we examine those concerns using traditional psychometric methods...
  7. pmc A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)
    Afsane Riazi
    Department of Psychology, Royal Holloway, University of London, Surrey, TW20 0EX, UK
    Health Qual Life Outcomes 9:80. 2011
    ..We report the development of a rating scale to measure patient's experiences of relapse management that allowed this question to be answered confidently...
  8. pmc The size of the treatment effect: do patients and proxies agree?
    Femke A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    BMC Neurol 9:12. 2009
    ..This may be of interest in situations when patients suffer from limitations that interfere with reliable self-assessment, such as cognitive impairment...
  9. ncbi request reprint Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)
    J C Hobart
    Department of Clinical Neuroscience, Peninsula Medical School, Plymouth, Devon, UK
    Brain 129:224-34. 2006
    ..It has the potential to advance outcomes measurement in clinical trials and clinical practice, and provides a new perspective in the clinical evaluation of spasticity...
  10. pmc How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales
    J C Hobart
    Murdoch University, Perth, Western Australia
    J Neurol Neurosurg Psychiatry 76:1539-43. 2005
    ..To estimate the impact on clinical trials of differing scale responsiveness...
  11. ncbi request reprint Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?
    Afsane Riazi
    Neurological Outcomes Measures Unit, Institute of Neurology, London, United Kingdom
    Mov Disord 21:1396-403. 2006
    ..Results highlight the potential limitations of these four scales for evaluating health outcomes in FA and suggest the need for new disease-specific patient-based measures of its impact...
  12. doi request reprint Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies
    Stefan J Cano
    Neurological Outcome Measures Unit, Institute of Neurology, University College London, London, United Kingdom
    Mov Disord 24:984-92. 2009
    ..Importantly, all versions can be referred back to the original scale. This study shows one of the many clinical advantages of using Rasch measurement methods to construct rating scales...
  13. ncbi request reprint Evidence-based guidelines for using the Short Form 36 in cervical dystonia
    Stefan J Cano
    Neurological Outcomes Measures Unit, Institute of Neurology, University College London, United Kingdom
    Mov Disord 22:122-6. 2007
    ..Evidence did not support computing SF-36 Physical and Mental Component Summary scores. We propose guidelines that include the recommendation that these subscale and summary scores should be reported with caution...
  14. ncbi request reprint International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?
    Stefan J Cano
    Department of Clinical Neurosciences, Royal Free and University College Medical School, London, UK
    Mov Disord 20:1585-91. 2005
    ..Further validity testing, and examination of responsiveness, is required before the ICARS can be recommended as an outcome measure for treatment trials of FDRA...
  15. ncbi request reprint Exploring rating scale responsiveness: does the total score reflect the sum of its parts?
    Rory J O'Connor
    Neurological Outcome Measures Unit, Institute of Neurology, University College London, UK
    Neurology 62:1842-4. 2004
    ..09). Item-level effect sizes (0.13 to 1.16) reveal floor (3.5 to 82.3%) and ceiling (9.7 to 95.4%) effects. Results suggest BI total score effect sizes may hide item-level weaknesses and may underestimate the impact of rehabilitation...
  16. doi request reprint The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts
    Stefan J Cano
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK
    J Neurol Neurosurg Psychiatry 81:1363-8. 2010
    ..Objective To examine the traditional psychometric properties of the ADAS-cog in a large sample of people with Alzheimer's disease...
  17. doi request reprint What sample sizes for reliability and validity studies in neurology?
    Jeremy C Hobart
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Tamar Science Park, Room N13 ITTC Building, Davy Road, Plymouth, UK
    J Neurol 259:2681-94. 2012
    ..These findings should be considered provisional and more work is needed to determine if these estimates are generalisable, consistent, and useful...
  18. doi request reprint Multiple sclerosis and extract of cannabis: results of the MUSEC trial
    John Peter Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, University of Plymouth, Derriford, UK
    J Neurol Neurosurg Psychiatry 83:1125-32. 2012
    ..Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of previous studies...
  19. ncbi request reprint Socio-demographic variables are limited predictors of health status in multiple sclerosis
    Afsane Riazi
    Neurological Outcome Measures Unit, Institute of Neurology, London, UK
    J Neurol 250:1088-93. 2003
    ..The aim of this study was to examine the predictive value of routinely collected socio-demographic variables on health status...
  20. doi request reprint Watch out, watch out, the FDA are about
    Stefan J Cano
    Neurological Outcome Measures Unit, Peninsula College of Medicine and Dentistry, Plymouth, London, UK
    Dev Med Child Neurol 50:408-9. 2008
  21. pmc Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort
    John P Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, University of Plymouth, UK
    BMC Neurol 10:88. 2010
    ....
  22. ncbi request reprint Quality of life measurement after stroke: uses and abuses of the SF-36
    Jeremy C Hobart
    Neurological Outcome Measures Unit, Institute of Neurology, Queen Square, London, United Kingdom
    Stroke 33:1348-56. 2002
    ..However, a fundamental assumption for its valid use after stroke has not been comprehensively tested: is it legitimate to generate scores for 8 scales and 2 summary measures using the standard algorithms? We tested this assumption...
  23. pmc The problem with health measurement
    Stefan J Cano
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Tamar Science Park, Plymouth, UK
    Patient Prefer Adherence 5:279-90. 2011
    ..This is because the methods we have in place to ensure the validity of rating scales fall short of what is actually required. We expand on this point, and provide some potential routes forward to help address this important problem...
  24. ncbi request reprint Patient-based outcomes of cervical dystonia: a review of rating scales
    Stefan J Cano
    Department of Clinical Neurosciences, Royal Free and University College Medical School, London, United Kingdom
    Mov Disord 19:1054-9. 2004
    ..This study reviewed rating scales used in cervical dystonia outcome research to determine the extent that they satisfy recommended criteria for rigorous measurement...